C12Y 305/04004
Adenosine deaminase
Official title: Adenosine deaminase (3.5.4.4)
C12Y305/04004 (Adenosine deaminase) appears on 113 US grants and 351 published applications in this corpus.
Search patents in C12Y- Granted patents
- 113
- Published applications
- 351
- Assignees
- 127
- Inventors
- 637
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1998 | 1 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 1 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 2 |
| 2007 | 0 | 0 |
| 2008 | 0 | 1 |
| 2009 | 0 | 2 |
| 2010 | 0 | 0 |
| 2011 | 0 | 1 |
| 2012 | 1 | 0 |
| 2013 | 0 | 3 |
| 2014 | 5 | 3 |
| 2015 | 1 | 9 |
| 2016 | 2 | 4 |
| 2017 | 4 | 7 |
| 2018 | 5 | 7 |
| 2019 | 3 | 14 |
| 2020 | 9 | 14 |
| 2021 | 8 | 25 |
| 2022 | 8 | 48 |
| 2023 | 17 | 55 |
| 2024 | 13 | 51 |
| 2025 | 17 | 57 |
| 2026 | 19 | 47 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- DCAS13-mediated therapeutic RNA base editing for in vivo gene therapy29 Sep 2026US 12,746,295 B2University of Massachusetts
- Adenine deaminases and compositions, systems, and methods thereof29 Sep 2026US 12,747,436 B2Profluent Bio Inc.
- Compositions comprising a CAS12I polypeptide and uses thereof29 Sep 2026US 12,747,457 B2Arbor Biotechnologies, Inc.
- RNA expression modulating or editing method via regulation of Cas13 protein18 Aug 2026US 12,709,742 B2Korea Advanced Institute of Science and Technology
- Fusion constructs and methods of using thereof11 Aug 2026US 12,703,747 B2Precigen, Inc.
- Rna preparations comprising purified modified rna for reprogramming cells1 Oct 2026US 2026/0297538 A1The Trustees of the University of Pennsylvania
- Compositions and methods including rna-binding proteins24 Sep 2026US 2026/0286325 A1Regents of the University of Minnesota
- Woolly mammoth specific gene variants and compositions comprising same17 Sep 2026US 2026/0274907 A1Colossal Biosciences Inc.
- Compositions and methods for altering complement activation10 Sep 2026US 2026/0263501 A1Apellis Pharmaceuticals, Inc.
- Base editing approaches for correcting the ivs2-1...10 Sep 2026US 2026/0263635 A1Assistance Publique-HôPitaux De Paris (Aphp)
Most cited
By later US patents
- RNA containing modified nucleosides and methods of use thereof353US 8,278,036 B2The Trustees of the University of Pennsylvania · 2012
- RNA containing modified nucleosides and methods of use thereof230US 8,691,966 B2The Trustees of the University of Pennsylvania · 2014
- RNA containing modified nucleosides and methods of use thereof222US 8,748,089 B2The Trustees of the University of Pennsylvania · 2014
- RNA containing modified nucleosides and methods of use thereof198US 8,835,108 B2The Trustees of the University of Pennsylvania · 2014
- Methods for correcting presenilin point mutations123US 9,068,179 B1President and Fellows of Harvard College · 2015